Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > COLUMN
COLUMN
-
Maurer's Healthcare Insight (86)
May 28, 2007
-
Maurer's Healthcare Insight (85)
April 16, 2007
-
Maurer's Healthcare Insight (84)
March 26, 2007
-
Japan's Most Admired Pharma Companies in 2006 P. Reed Maurer
March 12, 2007
-
Maurer's Healthcare Insight (83)
February 19, 2007
-
2006: When the Pendulum Swung P. Reed Maurer
January 8, 2007
-
Maurer's Healthcare Insight (82)／Questions from the Floor P. Reed Maurer
December 18, 2006
-
Maurer's Healthcare Insight (81)
November 20, 2006
-
Maurer's Healthcare Insight (80)
October 23, 2006
-
Maurer's Healthcare Insight (79) Back from the Saddle P. Reed Maurer
September 25, 2006
-
Maurer's Healthcare Insight (78) Infinite Value of a Good Boss P. Reed Maurer
August 28, 2006
-
Maurer's Healthcare Insight (77)
July 24, 2006
-
Maurer's Healthcare Insight (76)
June 26, 2006
-
Maurer's Healthcare Insight (75)
May 29, 2006
-
Maurer's Healthcare Insight (74)
April 10, 2006
-
Maurer's Healthcare Insight (73)
March 13, 2006
-
Maurer's Healthcare Insight (71)
December 19, 2005
-
Maurer's Healthcare Insight (70)
November 28, 2005
-
Maurer's Healthcare Insight(69)
November 14, 2005
-
Maurer's Healthcare Insight (68)
October 17, 2005
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…